FDA Panel Recommends Stricter Regulatory Standards For All Rapid Influenza Tests
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Microbiology Devices Advisory agrees with FDA’s proposals June 13 to move rapid flu antigen tests to class II with new sensitivity and specificity thresholds and post-market standards to address concerns with poor performance.
You may also be interested in...
US Regulatory News Briefs
Updates on flu-assay regulation, an upcoming eye-care panel, and an FDA safety note on implantable infusion pump risks with MRI.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.